

# The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial

Published: 07-07-2017

Last updated: 13-04-2024

The objective of this study is to investigate whether BTA injection in the pelvic floor muscle is an effective treatment for patients with chronic pelvic pain and pelvic floor hypertonicity.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Other condition
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON48791

### Source

ToetsingOnline

### Brief title

Botulinum toxin A injection in pelvic floor muscles

### Condition

- Other condition
- Muscle disorders
- Soft tissue therapeutic procedures

### Synonym

chronic pelvic pain, pelvic floor muscle hypertonicity

### Health condition

chronische bekkenpijn

## Research involving

Human

## Sponsors and support

**Primary sponsor:** Radboud Universitair Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** botulin, hypertonicity, pelvic floor muscles, pelvic pain

## Outcome measures

### Primary outcome

Decrease of chronic pelvic pain, measured with a decrease in visual analog scale score (VAS score 0-10) with 33% and the PGI-I of 6 or 7 (better or much better).

### Secondary outcome

- Quality of life measured with validated questionnaires: patient global impression of improvement score (PGI-I), pelvic floor distress inventory (PFDI-20), pelvic floor impact questionnaire (PFIQ-7), quality of life (EQ-5D), paindetect, pain catastrophizing scale (PCS), hospital anxiety and depression scale (HADS), sexual function (FSDS, FSFI).
- Decrease of pelvic floor hypertonicity measured by the MAPLe device
- Patient preference study: evaluating patient preferences in maximal treatment effect at cost of possible side-effects.

## Study description

### Background summary

Chronic pelvic pain is common, affecting 15% of women aged 18-50 [Mathias]. Pelvic floor muscle spasms resulting in chronic pelvic pain may occur as a primary event or secondary to a physical, psychological or pathological factor. First-line treatment consists of pelvic floor physiotherapy. When first-line treatment fails, more invasive interventions can take place. One described intervention is injection with Botulinum toxin A (BTA) in the pelvic floor muscles. It produces a localized, partial, and reversible chemical denervation of the muscle which results in localized muscle weakness or paralysis. There is some evidence that injection of BTA in the hypertonic pelvic floor muscles decreases pelvic pain in patients with therapy resistant chronic pelvic pain, however this is not investigated in a randomized controlled trial.

## **Study objective**

The objective of this study is to investigate whether BTA injection in the pelvic floor muscle is an effective treatment for patients with chronic pelvic pain and pelvic floor hypertonicity.

## **Study design**

Double-blinded randomized placebo-controlled cross-over trial

## **Intervention**

The pelvic floor muscles will be injected with either 100 IU BTA or NaCl 0.9% (placebo).

## **Study burden and risks**

Patients will undergo one of two vaginal injections with BTA or placebo. To evaluate efficacy, questionnaires and physical examination will be performed at baseline, t=4, 8, 12, and 26 weeks after injection. The discomfort will mainly be during the injection, this will last for maximal 15 minutes. Risks of injection will be bleeding or infections which are anticipated by hemostatic pressure and antiseptic workflow and are considered minimal. Side-effects as temporarily urinary and/or fecal incontinence will be discussed before inclusion (0-6%).

## **Contacts**

### **Public**

Radboud Universitair Medisch Centrum

geert grooteplein zuid 10

nijmegen 6525ga

NL

### **Scientific**

Radboud Universitair Medisch Centrum

geert grooteplein zuid 10

nijmegen 6525ga

NL

## **Trial sites**

### **Listed location countries**

Netherlands

## **Eligibility criteria**

### **Age**

Adults (18-64 years)

Elderly (65 years and older)

### **Inclusion criteria**

- Female, >16 years
- Chronic pelvic pain according to the ICS with or without dyspareunia
- Vaginal examination with one finger possible
- Pelvic floor hypertonicity measured by physical examination by registered pelvic floor physiotherapist
- Previous physical therapy with registered physical therapist was unsuccessful
- Good understanding of Dutch language
- Willing to provide informed consent

### **Exclusion criteria**

- (wish for) Pregnancy/lactation during study period
- Previous pelvic floor botox treatment
- Known hypersensitivity to botox
- History of neuromuscular or bleeding disorders

## Study design

### Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	07-01-2020
Enrollment:	94
Type:	Actual

### Medical products/devices used

Product type:	Medicine
Brand name:	botox
Generic name:	botulin toxin A
Registration:	Yes - NL outside intended use

## Ethics review

Approved WMO	
Date:	07-07-2017
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	03-06-2019
Application type:	First submission

Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	15-07-2019
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	02-10-2019
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	31-10-2019
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
EudraCT	EUCTR2017-001296-23-NL
CCMO	NL61409.091.17